L-005-2024
Agreement ID
L-005-2024
Lead IC
NIAID
Exclusivity
Nonexclusive
External Party
Vicebio Ltd.
Fiscal Year
2025
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-2717 Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
TAB-3342 Fusion Glycoprotein Vaccine for Human Metapneumovirus
TAB-3336 Substitutions-Modified Prefusion RSV F Proteins and Their Use
TAB-3310 Prefusion HPIV F Immunogens and Their Use.
TAB-3429 Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus
TAB-3342 Fusion Glycoprotein Vaccine for Human Metapneumovirus
TAB-3336 Substitutions-Modified Prefusion RSV F Proteins and Their Use
TAB-3310 Prefusion HPIV F Immunogens and Their Use.
TAB-3429 Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus